You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrichlormethiazide
Accession NumberDB01021  (APRD00031)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

Structure
Thumb
Synonyms
Naqua
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnistadinNot Available
CarvacronNot Available
Diu-HydrinNot Available
DiureseNot Available
FluitranNot Available
KubacronNot Available
MetahydrinNot Available
NaquaNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIQ58C92TUN0
CAS number133-67-5
WeightAverage: 380.656
Monoisotopic: 378.90218026
Chemical FormulaC8H8Cl3N3O4S2
InChI KeyInChIKey=LMJSLTNSBFUCMU-UHFFFAOYSA-N
InChI
InChI=1S/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)
IUPAC Name
6-chloro-3-(dichloromethyl)-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C(Cl)Cl
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl chloride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in the treatment of oedema (including that associated with heart failure) and hypertension.
PharmacodynamicsTrichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionTrichlormethiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, Trichloromethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like Trichloromethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of Trichloromethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral Rat LD50 = 5600 mg/kg, oral Mouse LD50 = 2600 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Trichlormethiazide Action PathwayDrug actionSMP00121
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9356
Blood Brain Barrier-0.9431
Caco-2 permeable-0.7869
P-glycoprotein substrateNon-substrate0.6958
P-glycoprotein inhibitor INon-inhibitor0.8804
P-glycoprotein inhibitor IINon-inhibitor0.9432
Renal organic cation transporterNon-inhibitor0.8959
CYP450 2C9 substrateNon-substrate0.7173
CYP450 2D6 substrateNon-substrate0.8454
CYP450 3A4 substrateNon-substrate0.6828
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9454
CYP450 2D6 inhibitorNon-inhibitor0.9582
CYP450 2C19 inhibitorNon-inhibitor0.9611
CYP450 3A4 inhibitorNon-inhibitor0.9325
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9502
Ames testNon AMES toxic0.9209
CarcinogenicityNon-carcinogens0.844
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8282 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9721
hERG inhibition (predictor II)Non-inhibitor0.9276
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sanofi aventis us llc
  • Schering corp sub schering plough corp
  • Lannett co inc
  • Mm mast and co
  • Impax laboratories inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Tg united labs llc
  • Watson laboratories inc
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Trichlormethiazide powder15.0USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point270 dec °CPhysProp
water solubility800 mg/L (at 25 °C)MERCK (1989)
logP0.62SANGSTER (1994)
logS-2.68ADME Research, USCD
pKa8.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.415 mg/mLALOGPS
logP0.86ALOGPS
logP0.97ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)8.32ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity77.44 m3·mol-1ChemAxon
Polarizability31.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.06 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC03AA06C03AB06C03EA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Trichlormethiazide.
AcetaminophenAcetaminophen may increase the orthostatic hypotensive activities of Trichlormethiazide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trichlormethiazide.
AclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Aclidinium.
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Trichlormethiazide.
AlfacalcidolTrichlormethiazide may increase the hypercalcemic activities of Alfacalcidol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Trichlormethiazide.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Trichlormethiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Trichlormethiazide.
AmitriptylineThe serum concentration of Trichlormethiazide can be increased when it is combined with Amitriptyline.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
AmoxapineThe serum concentration of Trichlormethiazide can be increased when it is combined with Amoxapine.
ArformoterolArformoterol may increase the hypokalemic activities of Trichlormethiazide.
AtropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Atropine.
AzelastineThe serum concentration of Trichlormethiazide can be increased when it is combined with Azelastine.
BenazeprilTrichlormethiazide may increase the hypotensive activities of Benazepril.
BenzatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Benzatropine.
BetamethasoneBetamethasone may increase the hypokalemic activities of Trichlormethiazide.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Trichlormethiazide.
BrompheniramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Brompheniramine.
BudesonideBudesonide may increase the hypokalemic activities of Trichlormethiazide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Trichlormethiazide.
ButabarbitalButabarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
ButalbitalButalbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichlormethiazide.
CaffeineCaffeine may increase the orthostatic hypotensive activities of Trichlormethiazide.
CalcipotriolTrichlormethiazide may increase the hypercalcemic activities of Calcipotriol.
CalcitriolTrichlormethiazide may increase the hypercalcemic activities of Calcitriol.
Calcium AcetateTrichlormethiazide may decrease the excretion rate of Calcium Acetate which could result in a lower serum level and potentially a reduction in efficacy.
Calcium carbonateTrichlormethiazide may decrease the excretion rate of Calcium carbonate which could result in a lower serum level and potentially a reduction in efficacy.
Calcium ChlorideTrichlormethiazide may decrease the excretion rate of Calcium Chloride which could result in a lower serum level and potentially a reduction in efficacy.
Calcium citrateTrichlormethiazide may decrease the excretion rate of Calcium citrate which could result in a lower serum level and potentially a reduction in efficacy.
Calcium gluconateTrichlormethiazide may decrease the excretion rate of Calcium gluconate which could result in a lower serum level and potentially a reduction in efficacy.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.
CaptoprilTrichlormethiazide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.
CarbinoxamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Carbinoxamine.
CelecoxibThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.
CetirizineThe serum concentration of Trichlormethiazide can be increased when it is combined with Cetirizine.
ChlordiazepoxideThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlordiazepoxide.
ChlorphenamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Trichlormethiazide.
CholecalciferolTrichlormethiazide may increase the hypercalcemic activities of Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilTrichlormethiazide may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the activities of Trichlormethiazide.
ClemastineThe serum concentration of Trichlormethiazide can be increased when it is combined with Clemastine.
ClidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Clidinium.
ClofedanolThe serum concentration of Trichlormethiazide can be increased when it is combined with Clofedanol.
ClomipramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Clomipramine.
ClozapineThe serum concentration of Trichlormethiazide can be increased when it is combined with Clozapine.
CodeineThe serum concentration of Trichlormethiazide can be increased when it is combined with Codeine.
ColesevelamColesevelam can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Trichlormethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CorticotropinCorticotropin may increase the hypokalemic activities of Trichlormethiazide.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Trichlormethiazide.
CyclizineThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclizine.
CyclobenzaprineThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclobenzaprine.
CyclopentolateThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Cyclophosphamide.
CyproheptadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyproheptadine.
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Trichlormethiazide.
DarifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin.
DesipramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Desloratadine.
DexamethasoneDexamethasone may increase the hypokalemic activities of Trichlormethiazide.
DexbrompheniramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Dexbrompheniramine.
Dexchlorpheniramine maleateThe serum concentration of Trichlormethiazide can be increased when it is combined with Dexchlorpheniramine maleate.
DiazoxideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diclofenac.
DicyclomineThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.
DifenoxinThe serum concentration of Trichlormethiazide can be increased when it is combined with Difenoxin.
DiflunisalThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.
DigoxinThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Trichlormethiazide.
DimenhydrinateThe serum concentration of Trichlormethiazide can be increased when it is combined with Dimenhydrinate.
DiphenhydramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Diphenhydramine.
DiphenoxylateThe serum concentration of Trichlormethiazide can be increased when it is combined with Diphenoxylate.
DisopyramideThe serum concentration of Trichlormethiazide can be increased when it is combined with Disopyramide.
DofetilideTrichlormethiazide may increase the QTc-prolonging activities of Dofetilide.
DoxepinThe serum concentration of Trichlormethiazide can be increased when it is combined with Doxepin.
DoxercalciferolTrichlormethiazide may increase the hypercalcemic activities of Doxercalciferol.
DoxylamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Doxylamine.
DroperidolThe serum concentration of Trichlormethiazide can be increased when it is combined with Droperidol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Trichlormethiazide.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.
EnalaprilTrichlormethiazide may increase the hypotensive activities of Enalapril.
EnalaprilatTrichlormethiazide may increase the hypotensive activities of Enalaprilat.
ErgocalciferolTrichlormethiazide may increase the hypercalcemic activities of Ergocalciferol.
EscitalopramEscitalopram may increase the activities of Trichlormethiazide.
EtodolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etodolac.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Trichlormethiazide.
FenoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Trichlormethiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Trichlormethiazide.
FesoterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Fesoterodine.
FexofenadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Fexofenadine.
FlavoxateThe serum concentration of Trichlormethiazide can be increased when it is combined with Flavoxate.
FloctafenineThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.
FluoxetineFluoxetine may increase the activities of Trichlormethiazide.
FlupentixolThe serum concentration of Trichlormethiazide can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Fluphenazine.
FlurbiprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone PropionateThe serum concentration of Trichlormethiazide can be increased when it is combined with Fluticasone Propionate.
FluvoxamineFluvoxamine may increase the activities of Trichlormethiazide.
FormoterolFormoterol may increase the hypokalemic activities of Trichlormethiazide.
FosinoprilTrichlormethiazide may increase the hypotensive activities of Fosinopril.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Trichlormethiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Trichlormethiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Trichlormethiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Trichlormethiazide.
GlycopyrroniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Glycopyrrolate.
HaloperidolThe serum concentration of Trichlormethiazide can be increased when it is combined with Haloperidol.
HomatropineThe serum concentration of Trichlormethiazide can be increased when it is combined with Homatropine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Trichlormethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trichlormethiazide.
HydroxyzineThe serum concentration of Trichlormethiazide can be increased when it is combined with Hydroxyzine.
HyoscyamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ibuprofen.
ImipramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the hypokalemic activities of Trichlormethiazide.
IndomethacinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Trichlormethiazide.
Insulin DegludecThe therapeutic efficacy of Insulin degludec can be decreased when used in combination with Trichlormethiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Trichlormethiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Trichlormethiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Trichlormethiazide.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Trichlormethiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.
Ipratropium bromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.
IsocarboxazidThe serum concentration of Trichlormethiazide can be increased when it is combined with Isocarboxazid.
IvabradineTrichlormethiazide may increase the arrhythmogenic activities of Ivabradine.
KetoprofenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketorolac.
LevocabastineThe serum concentration of Trichlormethiazide can be increased when it is combined with Levocabastine.
LevocetirizineThe serum concentration of Trichlormethiazide can be increased when it is combined with Levocetirizine.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Trichlormethiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Trichlormethiazide.
LisinoprilTrichlormethiazide may increase the hypotensive activities of Lisinopril.
LithiumTrichlormethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LoratadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Loratadine.
LoxapineThe serum concentration of Trichlormethiazide can be increased when it is combined with Loxapine.
MaprotilineThe serum concentration of Trichlormethiazide can be increased when it is combined with Maprotiline.
MeclizineThe serum concentration of Trichlormethiazide can be increased when it is combined with Meclizine.
Mefenamic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.
MeloxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meloxicam.
MepenzolateThe serum concentration of Trichlormethiazide can be increased when it is combined with Mepenzolate.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Trichlormethiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Trichlormethiazide.
MethotrimeprazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Methotrimeprazine.
MethscopolamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Methscopolamine.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Trichlormethiazide.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Trichlormethiazide.
MoclobemideThe serum concentration of Trichlormethiazide can be increased when it is combined with Moclobemide.
MoexiprilTrichlormethiazide may increase the hypotensive activities of Moexipril.
MometasoneMometasone may increase the hypokalemic activities of Trichlormethiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Trichlormethiazide.
NabumetoneThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nabumetone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Trichlormethiazide.
NaproxenThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Trichlormethiazide.
NortriptylineThe serum concentration of Trichlormethiazide can be increased when it is combined with Nortriptyline.
OlanzapineThe serum concentration of Trichlormethiazide can be increased when it is combined with Olanzapine.
OlodaterolOlodaterol may increase the hypokalemic activities of Trichlormethiazide.
OlopatadineThe serum concentration of Trichlormethiazide can be increased when it is combined with Olopatadine.
OrphenadrineThe serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine.
OxaprozinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Oxcarbazepine.
OxybutyninThe serum concentration of Trichlormethiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trichlormethiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Trichlormethiazide.
ParicalcitolTrichlormethiazide may increase the hypercalcemic activities of Paricalcitol.
ParoxetineParoxetine may increase the activities of Trichlormethiazide.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trichlormethiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
PerindoprilTrichlormethiazide may increase the hypotensive activities of Perindopril.
PerphenazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trichlormethiazide.
PhenelzineThe serum concentration of Trichlormethiazide can be increased when it is combined with Phenelzine.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
PimozideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Trichlormethiazide.
PirbuterolPirbuterol may increase the hypokalemic activities of Trichlormethiazide.
PiroxicamThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.
PizotifenThe serum concentration of Trichlormethiazide can be increased when it is combined with Pizotifen.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Trichlormethiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Trichlormethiazide.
PrednisonePrednisone may increase the hypokalemic activities of Trichlormethiazide.
ProchlorperazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Prochlorperazine.
ProcyclidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Procyclidine.
PromazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Promazine.
PromethazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Promethazine.
PropanthelineThe serum concentration of Trichlormethiazide can be increased when it is combined with Propantheline.
ProtriptylineThe serum concentration of Trichlormethiazide can be increased when it is combined with Protriptyline.
QuetiapineThe serum concentration of Trichlormethiazide can be increased when it is combined with Quetiapine.
QuinaprilTrichlormethiazide may increase the hypotensive activities of Quinapril.
RamiprilTrichlormethiazide may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Trichlormethiazide.
Repository corticotropinRepository corticotropin may increase the hypokalemic activities of Trichlormethiazide.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Trichlormethiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Trichlormethiazide.
SalmeterolSalmeterol may increase the hypokalemic activities of Trichlormethiazide.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Trichlormethiazide.
ScopolamineThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
SertralineSertraline may increase the activities of Trichlormethiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Trichlormethiazide.
SolifenacinThe serum concentration of Trichlormethiazide can be increased when it is combined with Solifenacin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.
SulindacThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulindac.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trichlormethiazide.
TerbutalineTerbutaline may increase the hypokalemic activities of Trichlormethiazide.
ThioridazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Thioridazine.
ThiothixeneThe serum concentration of Trichlormethiazide can be increased when it is combined with Thiothixene.
Tiaprofenic acidThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tiaprofenic acid.
TiotropiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Tiotropium.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Trichlormethiazide.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Trichlormethiazide.
TolmetinThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tolmetin.
TolterodineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tolterodine.
TopiramateTrichlormethiazide may increase the hypokalemic activities of Topiramate.
ToremifeneTrichlormethiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.
TrandolaprilTrichlormethiazide may increase the hypotensive activities of Trandolapril.
TranylcypromineThe serum concentration of Trichlormethiazide can be increased when it is combined with Tranylcypromine.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Trichlormethiazide can be increased when it is combined with Trifluoperazine.
TrihexyphenidylThe serum concentration of Trichlormethiazide can be increased when it is combined with Trihexyphenidyl.
TrimethobenzamideThe serum concentration of Trichlormethiazide can be increased when it is combined with Trimethobenzamide.
TrimipramineThe serum concentration of Trichlormethiazide can be increased when it is combined with Trimipramine.
TriprolidineThe serum concentration of Trichlormethiazide can be increased when it is combined with Triprolidine.
TrospiumThe serum concentration of Trichlormethiazide can be increased when it is combined with Trospium.
UmeclidiniumThe serum concentration of Trichlormethiazide can be increased when it is combined with Umeclidinium.
VilanterolVilanterol may increase the hypokalemic activities of Trichlormethiazide.
VilazodoneVilazodone may increase the activities of Trichlormethiazide.
VortioxetineVortioxetine may increase the activities of Trichlormethiazide.
ZuclopenthixolThe serum concentration of Trichlormethiazide can be increased when it is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Li J, Wang DH: Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. [PubMed:17414671 ]
  2. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H: Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9. Epub 2003 Nov 10. [PubMed:14610216 ]
  3. Smith SM: Thiazide diuretics. N Engl J Med. 2010 Feb 18;362(7):659-60; author reply 660. [PubMed:20187262 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Takahashi N, Kondo Y, Fujiwara I, Ito O, Igarashi Y, Abe K: Characterization of Na+ transport across the cell membranes of the ascending thin limb of Henle's loop. Kidney Int. 1995 Mar;47(3):789-94. [PubMed:7752578 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thiopurine s-methyltransferase activity
Specific Function:
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name:
TPMT
Uniprot ID:
P51580
Molecular Weight:
28180.09 Da
References
  1. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J: Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol. 1996;49(5):393-6. [PubMed:8866635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23